Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 4/1/22 → 2/14/24 |
Funding
- Swarn Incorporated: $9,749.00
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of AMZ002, Compared to Vigabatrin, in the Treatment of Infantile Spasms
- Khan, Gulam (PI)